Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Shares Issued (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Shares Issued data on record, last reported at $376000.0 in Q4 2025.

  • For Q4 2025, Shares Issued rose 154.05% year-over-year to $376000.0; the TTM value through Dec 2025 reached $4.1 million, up 91.23%, while the annual FY2025 figure was $4.1 million, 91.23% up from the prior year.
  • Shares Issued reached $376000.0 in Q4 2025 per AMLX's latest filing, down from $2.7 million in the prior quarter.
  • Across five years, Shares Issued topped out at $200.9 million in Q1 2022 and bottomed at $3000.0 in Q2 2021.
  • Average Shares Issued over 5 years is $12.6 million, with a median of $376000.0 recorded in 2025.
  • Peak YoY movement for Shares Issued: skyrocketed 647954.84% in 2022, then crashed 98.24% in 2023.
  • A 5-year view of Shares Issued shows it stood at $145000.0 in 2021, then surged by 138449.66% to $200.9 million in 2022, then tumbled by 99.83% to $347000.0 in 2023, then crashed by 57.35% to $148000.0 in 2024, then soared by 154.05% to $376000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $376000.0 in Q4 2025, $2.7 million in Q3 2025, and $72000.0 in Q2 2025.